Clinical Trial Update: Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study [Phase 2]

View source ↗

Summary

Phase 2 CABATEN trial evaluated cabozantinib in combination with atezolizumab for advanced neuroendocrine neoplasms of the endocrine system. The study has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma
• Anaplastic Thyroid Carcinoma
• Neuroendocrine Tumor
• Paraganglioma
• Pheochromocytoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• cabozantinib (cabozantinib)

Snippet

Sponsor: Grupo Espanol de Tumores Neuroendocrinos | Conditions: Neuroendocrine Tumor, Anaplastic Thyroid Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-06-19